回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验以及回复：CYP2D6和UGT2B7基因分型与他莫昔芬治疗的乳腺癌患者复发风险 - Suppr

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

作者信息

Pharoah Paul D P, Abraham Jean, Caldas Carlos

出版信息

J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.

DOI:10.1093/jnci/djs312

PMID:22851268

Abstract

摘要

相似文献

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8. doi: 10.1093/jnci/djs305. Epub 2012 Jul 31.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31.

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

J Natl Cancer Inst. 2008 Sep 17;100(18):1331-2; author reply 132-3. doi: 10.1093/jnci/djn272. Epub 2008 Sep 9.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.

Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

J Natl Cancer Inst. 2008 Sep 17;100(18):1331; author reply 1332-4. doi: 10.1093/jnci/djn269. Epub 2008 Sep 9.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

引用本文的文献

Clinical Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy.

Cancers (Basel). 2021 Feb 12;13(4):771. doi: 10.3390/cancers13040771.

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.

Breast Cancer Res. 2018 Dec 10;20(1):149. doi: 10.1186/s13058-018-1083-y.

Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.

Clin Transl Sci. 2018 May;11(3):312-321. doi: 10.1111/cts.12542. Epub 2018 Feb 13.

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17.

Breast cancer recurrence in relation to antidepressant use.

Cancer Causes Control. 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. Epub 2015 Oct 30.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

J Natl Cancer Inst. 2014 Dec 8;107(2):dju401. doi: 10.1093/jnci/dju401.

Status of adjuvant endocrine therapy for breast cancer.

Breast Cancer Res. 2014;16(2):206. doi: 10.1186/bcr3636.

'Toxgnostics': an unmet need in cancer medicine.

Nat Rev Cancer. 2014 Jun;14(6):440-5. doi: 10.1038/nrc3729. Epub 2014 May 15.

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

J Natl Cancer Inst. 2014 Apr 3;106(5):dju063. doi: 10.1093/jnci/dju063.

Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Future Oncol. 2014 Jan;10(1):107-22. doi: 10.2217/fon.13.168.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

作者信息

出版信息

相似文献

引用本文的文献